Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Tumor Biol

Search In Journal Title:

Abbravation: Tumor Biology

Search In Journal Abbravation:

Publisher

Springer Netherlands

Search In Publisher:

DOI

10.1007/s11250-009-9385-9

Search In DOI:

ISSN

1423-0380

Search In ISSN:
Search In Title Of Papers:

Combination of platelet count and mean platelet vo

Authors: Fan Zhang Zhaoli Chen Pan Wang Xueda Hu Yibo Gao Jie He
Publish Date: 2016/01/16
Volume: 37, Issue: 7, Pages: 9323-9331
PDF Link

Abstract

The aim of this study is to search the most powerful prognostic factor from routine blood test for esophageal squamous cell cancer ESCC patients Multiple laboratory tests were evaluated including those reflecting red blood cell parameters hemoglobin Hb mean corpuscular volume MCV mean corpuscular hemoglobin concentration MCHC and red blood cell distribution width RDW platelet morphological parameters mean platelet volume MPV and platelet count PLT blood coagulation status Ddimer and tumor biomarker CA199 Known inflammatory indices NLR and PLR were also calculated A total of 468 patients who were diagnosed with ESCC between December 2005 and December 2008 were retrospectively analyzed in this study By utilizing univariate and multivariate Cox proportional hazard analyses we found that PLT and MPV were significantly associated with overall survival OS and diseasefree survival DFS of ESCC patients with optimal cutoff values of 212 and 106 respectively Moreover the combination of the preoperative PLT and MPV COPMPV was calculated as follows patients with both PLT ≥212 × 109 L−1 and MPV ≥106 fL elevation were assigned a score of 2 and patients with one or neither were assigned a score of 1 and 0 The COPMPV was an independent prognostic factor for OS hazard ratio HR 0378 95  confidence interval CI 0241 to 0593 P  0001 0/2 and DFS HR 0341 95  CI 0218 to 0534 P  0001 0/2 in multivariate analyses In subgroup analyses for early stages I and II and locally stage III advanced stage patients COPMPV was found significantly associated with OS and DFS in each group P = 0025 and P = 0018 for OS and P = 0029 and P = 0002 for DFS In conclusion we considered that COPMPV is a promising predictor for postoperative survival in ESCC patientsAmong the most lethal malignancies esophageal cancer EC ranks the sixth worldwide leading to approximately 400000 deaths in 2012 1 In China esophageal cancer is the fourth leading cause of all cancer deaths representing a major problem of public health in some highrisk rural areas 2 The dominant histopathological type of EC is squamous cell carcinoma ESCC in Chinese patients which covers 90  of all cases 3 Despite the progress in radical resection and adjuvant therapy radiation and chemotherapy ESCC still shows a poor 5year survival rate of less than 30  4 The tumor node metastasis TNM staging especially the status of lymph node metastasis is currently the best predictor for ESCC patient survival 5 Although several studies had identified certain survivalrelated biomarkers 6 7 8 they were less powerful and hardly able to be converted to clinical use Thus it is important to recognize effective and easyobtained biomarkers for ESCC prognosisIn the past decade platelet activation has been demonstrated as a crucial biological process in carcinogenesis and metastasis 9 10 11 Platelet count PLT and mean platelet volume MPV are two main characteristics to evaluate platelet activation 12 Patients with thrombocytosis have been reported to have worse prognosis in multiple solid tumors such as ovarian cancer 13 endometrial cancer 14 gastric cancer 15 and colorectal cancer 16 On the other hand high MPV reflected an abnormal rate of platelet production and stimulation 17 Recent studies revealed that MPV levels were relatively higher in tumor patients than in normal controls and associated with poor prognosis in some gastrointestinal neoplasms 18 19 20 However the predictive value of PLT combined with MPV for postsurgery survival in ESCC has not been yet investigatedIn this study we assessed and checked the prognostic value of preoperative PLT and MPV in 468 ESCC patients Moreover we took the utility of a novel prognostic system based on platelet activation termed combination of platelet count and MPV COPMPV which made a promising distinction between better and worse prognosis in both subgroups of early stages I and II and locally advanced stage stage III ESCC patientsPatients with histopathologically confirmed ESCC with no distal metastasis TNM stage I–III were enrolled in the study from December 2005 to December 2008 All patients underwent esophagectomy at the Cancer Institute and Hospital Chinese Academy of Medical Sciences CAMS with written informed consent The exclusion criteria were 1 severe complications or deaths occurred within 30 days after surgery 2 preoperative systemic inflammatory response syndrome SIRS 3 neoadjuvant radiotherapy or chemotherapy and 4 evidence of infection or autoimmune disease All patients underwent a careful preoperative evaluation including clinical history taking physical examination laboratory blood testing biochemistry complete blood cell counts coagulation status and serum tumor marker pulmonary function test and multiple radiography computed tomography CT or magnetic resonance imaging MRI Clinicopathological information of the patients were obtained from the medical records including age gender smoking history drinking status tumor location differentiation grade maximum tumor diameter lymph node metastasis TNM stage and history of adjuvant chemotherapy and radiotherapy The TNM stage was assessed according to American Joint Committee on Cancer AJCC staging manual seventh edition 21 Patients underwent adjuvant radio/chemotherapy after surgery according to TNM stages and family economic status The laboratory characteristics including hemoglobin Hb mean corpuscular volume MCV mean corpuscular hemoglobin concentration MCHC red blood cell distribution width RDW mean platelet volume MPV platelet count PLT Ddimer and CA199 were performed within 5 days prior to surgery The last followup date was July 9 2015 This study was approved by the medical ethics committee of the Cancer Institute and Hospital CAMSOverall survival OS was defined as follows the time from surgery to the time of patients’ death for any cause or the last followup date when the patient was known alive Diseasefree survival DFS was calculated from the date of operation to first tumor recurrence Neutrophillymphocyte ratio NLR/plateletlymphocyte ratio PLR was respectively defined as absolute neutrophil/lymphocyte count divided by absolute lymphocyte count Categorical variables were shown as frequency percentage while continuous variables were presented as the mean values ± standard deviation Unpaired t or χ 2 test was used to compare whether statistical differences between groups were significant The optimal cutoff values of all continuous variables were determined by receiver operating characteristic ROC curve We used univariate analysis to narrow down the list of possible prognostic factors Variables with P value  01 in univariate analysis were brought into multivariate Cox proportional hazard model to determine their independency Specifically the cutoff values of PLT and MPV were 212 ×109 L−1 and 106 fL respectively The COPMPV score was calculated on the basis of these two platelet characteristics Patients with both a higher platelet count ≥212 × 109 L−1 level and a higher mean platelet volume ≥106 fL level were grouped a score of 2 and patients with one or neither were grouped a score of 1 and 0 respectively KaplanMeier curves and logrank test were used to compare survival differences among groups All statistical analyses were conducted by SPSS 210 software IBM Corporation Somers NY USA P  005 was considered statistically significantA total of 468 patients were enrolled in this study including 376 men and 92 women The mean age of all patients was 595 ± 90 years median age 60 years range 36 to 81 Mean followup period was 491 ± 326 months range 32 to 1145 months Twohundred seventy 577  patients had died during the observation period The 5year overall survival rate was 450  for the whole cohort The distribution of TNM stages was stage I 46 98  stage II 199 426  and stage III 223 476  Mean PLT and MPV were 218 ± 65 × 109 L−1 range 52 to 611 and 106 ± 11 fL range 71 to 144 respectively Mean SD range levels of other selected laboratory variables or ratios were as follows Hb 145 gL−1 15 65 to 194 MCV 944 fL 51 767 to 1144 MCHC 342 gL−1 11 311 to 378 RDW 128  08 104 to 165 Ddimer 155 μg L−1 129 18 to 1522 CA199 1163 U mL−1 1383 035 to 14530 NLR 198 102 053 to 1100 and PLR 10966 4020 3279 to 41852


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor
  2. Interpretation of immunohistochemistry data of tumor should consider microenvironmental factors
  3. Interpretation of immunohistochemistry data of tumor should consider microenvironmental factors
  4. EphB4 is overexpressed in gliomas and promotes the growth of glioma cells
  5. Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis
  6. Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer
  7. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells
  8. Aberrant regulation of miR-15b in human malignant tumors and its effects on the hallmarks of cancer
  9. Glutathione S-transferase P1 Ile105Val polymorphism contributes to increased risk of gastric cancer in East Asians
  10. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia
  11. miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10
  12. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis
  13. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis
  14. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters
  15. Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis
  16. IL-17 gene polymorphism is associated with susceptibility to gastric cancer
  17. Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer
  18. SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion
  19. Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma
  20. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis
  21. Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target
  22. PGE 2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression
  23. Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women
  24. Association between x-ray repair cross-complementing group 3 ( XRCC3 ) genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population
  25. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair
  26. Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer
  27. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
  28. HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma
  29. MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus
  30. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy
  31. Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer
  32. Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis
  33. Alterations of circulating follicular helper T cells and interleukin 21 in diffuse large B-cell lymphoma
  34. Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype
  35. Investigation of circulating antibodies to ANXA1 in breast cancer
  36. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas
  37. Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population
  38. Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer
  39. Retraction Note to: Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study
  40. XRCC1 Arg399Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis
  41. The association between the APE1 Asp148Glu polymorphism and breast cancer susceptibility: a meta-analysis based on case–control studies
  42. Clinical significance and biological roles of CARMA3 in human bladder carcinoma
  43. RETRACTED ARTICLE: XRCC3 T241M polymorphism is associated risk of hepatocellular carcinoma in the Chinese
  44. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study
  45. RETRACTED ARTICLE: miR-203 suppression in gastric carcinoma promotes Slug-mediated cancer metastasis
  46. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620
  47. FAM172A is a tumor suppressor in colorectal carcinoma
  48. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma
  49. Kallikrein-related peptidase-6 ( KLK6 ) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma
  50. SMAD7 rs12953717 polymorphism contributes to increased risk of colorectal cancer
  51. Inhibitor of growth-4 is a potential target for cancer therapy
  52. Expression and biological role of cytoglobin in human ovarian cancer
  53. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma
  54. Epstein–Barr virus latent antigens EBNA3C and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis
  55. Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460
  56. The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma
  57. Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis
  58. Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma
  59. T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines
  60. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir
  61. Differential expression of inflammasomes in lung cancer cell lines and tissues
  62. MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1
  63. Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients
  64. Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance
  65. Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis
  66. Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia
  67. Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma
  68. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein
  69. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein
  70. Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging
  71. N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies
  72. Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma
  73. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis
  74. CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells
  75. Glycolytic activity with 18 F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer
  76. Regulation of autophagy by Ca 2+
  77. Differential gene expression of Wnt signaling pathway in benign, premalignant, and malignant human breast epithelial cells
  78. Mitochondrial D310 instability in Asian Indian breast cancer patients
  79. Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines
  80. Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma
  81. MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3
  82. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance
  83. Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients
  84. Runx2, a target gene for activating transcription factor-3 in human breast cancer cells
  85. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha- l -fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma
  86. HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer
  87. Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival
  88. The dual regulatory role of miR-204 in cancer
  89. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells
  90. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer
  91. Prognostic significance of GPC5 expression in patients with prostate cancer
  92. An updated meta-analysis of transforming growth factor-β1 gene: three polymorphisms with gastric cancer
  93. RETRACTED ARTICLE: Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma
  94. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle
  95. RETRACTED ARTICLE: Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR signaling-dependent MMP7 modulation
  96. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy
  97. Influence of different hypoxia models on metastatic potential of SGC-7901 gastric cancer cells
  98. Distribution of mast cells in benign odontogenic tumors
  99. Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma
  100. Mammary renin–angiotensin system-regulating aminopeptidase activities are modified in rats with breast cancer
  101. FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women
  102. The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies
  103. The expression of metabolism-related proteins in phyllodes tumors
  104. Pseudogene-expressed RNAs: a new frontier in cancers
  105. The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment
  106. Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?
  107. Pyruvate dehydrogenase B promoted the growth and migration of the nasopharyngeal carcinoma cells
  108. The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them
  109. Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy
  110. Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery
  111. XRCC1 R399Q polymorphism and colorectal cancer risk in the Chinese Han population: a meta-analysis
  112. Diagnostic value of CD117 in differential diagnosis of acute leukemias
  113. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen
  114. Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy
  115. Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk
  116. CIZ1 is upregulated in hepatocellular carcinoma and promotes the growth and migration of the cancer cells
  117. Missing link between microRNA and prostate cancer
  118. RETRACTED ARTICLE: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma

Search Result: